Company Overview and News

 
IL&FS unable to meet interest payment obligations

17h livemint
New Delhi: Infrastructure Leasing & Financial Services (IL&FS) was unable to service its obligations on interest payments on non-convertible debentures that were due on Friday, the company said in a statement.
500116 IDBI

 
Small lenders to submit report on stressed power assets by October 10

2018-09-21 moneycontrol
Small lenders will submit their resolution plans on stressed power assets to a group of bankers and assess the situation on October 10, Financial Express reported quoting people aware of the development.
PWQFY 500116 AXB IBN IDBI 532810 532215 AXBKY PFC AXBA ICICIBANK PNJZY 532461 AXISBANK 532174 PNB SBAZ

 
India looks to counter US curbs on Iran oil import

2018-09-21 freepressjournal.in
Washington : India is likely to resist the American pressure on complying with the reimposed Iranian sanctions as it has been a traditional policy of New Delhi to enforce only UNSC-authorised sanctions, a Congressional report has told lawmakers. The Trump administration has threatened entities and countries with consequences if they do not bring down their import of Iranian oil to zero by November 4.
IOC 500116 500325 IDBI RELIANCE RIGD 532505 530965 UCOBANK RLNIY

 
Refiners will pay for Iran oil in rupees after US sanctions kick in: Report

2018-09-20 moneycontrol
As petroleum-related sanctions on Iran come into effect from November 4, Indian refiners will pay for oil in Indian currency using UCO Bank and IDBI Bank, according to a report by The Economic Times.
IOC 500116 IDBI 532505 530965 UCOBANK

 
Belated merger but welcome

2018-09-20 freepressjournal.in
For over four years, the Government did virtually nothing to push the economic reforms, focusing, instead, on the nuts and bolts of the economic system, fixing leakages, removing bottlenecks and trying to work the inherited economic engine as well as it could. The disinvestment process was halted, the public sector was sought to be freed from government controls in the hope that it would turn the corner.
500116 532121 IDBI DENABANK SBAZ 532401 VIJAYABANK

 
Finance Minister to meet PSU banks chiefs next week; to review financial performance

2018-09-18 moneycontrol
Finance Minister Arun Jaitley will meet the heads of public sectors banks (PSBs) next week as part of the annual financial performance review exercise. The meeting scheduled for September 25 would discuss a host of issues, including progress made with regard to reduction in non-performing assets, sources said.
INDIANB 500116 PNJZY 532121 532461 IDBI 532814 PNB DENABANK 532401 VIJAYABANK

 
PSU banks correct sharply after govt announces merger of Vijaya Bank, Dena Bank and BoB

2018-09-18 moneycontrol
The government announced another step toward reform of PSU banks on Monday with merger of three PSBs Bank of Baroda, Vijaya Bank and Dena Bank but that seems to have not received well by the market on Tuesday.
INDIANB UBNC 500116 IDBI 532737 532418 532814 CNRYY 532401 VIJAYABANK SYNDIBANK 532276 EMKAY 532121 532483 CANBK DENABANK ANDHRABANK

 
IL&FS: It’s time for a surgery, not band-aid

2018-09-17 livemint
The question prospective rescuers of Infrastructure Leasing and Financial Services Ltd (IL&FS) should be asking is whether they should treat the symptoms or the disease. Life Insurance Corporation of India (LIC) is apparently readying a bailout and is likely to be in a position to effect management changes, subsequently.
500116 IDBI HDFC 500010 HDFC SBAZ

 
IDBI Bank Limited - Updates

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500116 IDBI

 
Watch: Vijay Mallya says, ‘I met Finance Minister before I left, repeated my offer to settle with banks’

2018-09-12 freepressjournal.in
Mumbai: Vijay Mallya dropped a big bomb so to say, when he told news agency ANI that he met the Finance Minster before leaving the country and offered to settle. “I met the Finance Minister before I left, repeated my offer to settle with the banks”, says Vijay Mallya outside London’s Westminster Magistrates’ Court.
500116 IDBI

 
IDBI Bank Limited - Updates

2018-09-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500116 IDBI

1
Why, really, did the INR fall?

2018-09-07 thehindubusinessline - 1
Sure, the dollar has risen against the currencies of most other emerging economies and, in the case of India, its huge dependence on imported crude oil, whose prices are rising, which results in a rising current account deficit, is another factor. For sure.
500116 IDBI

 
LIC-IDBI Bank deal given approval as an exception: IRDAI chief

2018-09-07 moneycontrol
The Insurance Regulatory and Development Authority of India (IRDAI) has said the LIC-IDBI Bank deal is an exception to the rules and has been granted permission looking at the merits of the case.
500116 LICHSGFIN IDBI LHFLY 500253

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...